Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
uniQure NVLTS:0EE0 -1.09%37 Debt-to-Equity is 0.19 as of Jun. 2026, which is 37% below its 10-year median of 0.30. GuruFocus rates LTS:0EE0 with a GF Score™ of 37/100 and a GF Value™ of $7.88 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 956 Biotechnology companies, uniQure NV ranks worse than 52.82% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for uniQure NV's Debt-to-Equity or its related term are showing as below:
LTS:0EE0'
s Debt-to-Equity Range Over the Past 10 Years
Min: -16.66 Med: 0.3 Max: 1.97
Current: 0.19
During the past 13 years, the highest Debt-to-Equity Ratio of uniQure NV was 1.97. The lowest was -16.66. And the median was 0.30.
LTS:0EE0's Debt-to-Equity is ranked worse than 52.82% of 956
companies
in the Biotechnology industry
Industry Median: 0.16
vs LTS:0EE0: 0.19
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
uniQure NV Debt-to-Equity Related Terms
uniQure NV Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for uniQure NV's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0EE0 vs ATAI, RARE, CLDX: Debt-to-Equity Comparison
For the Biotechnology subindustry, uniQure NV's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
uniQure NV Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, uniQure NV's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where uniQure NV's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
uniQure NV (LTS:0EE0) has a Debt-to-Equity of 0.19 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on uniQure NV and its competitors. This is 37% below median its historical median of 0.30. According to the industry distribution chart, uniQure NV ranks #505 out of 956 companies in the Biotechnology industry, placing it in the top 52.8%.
Is uniQure NV's Debt-to-Equity too high?
uniQure NV's current Debt-to-Equity of 0.19 is 37% below median its 10-year median of 0.30. The Biotechnology industry median Debt-to-Equity is 0.16. uniQure NV's value of 0.19 is 18.8% above this industry median. Based on the distribution chart, uniQure NV ranks #505 out of 956 companies in the Biotechnology industry, which is below the industry midpoint. Overall, uniQure NV has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does uniQure NV's Debt-to-Equity compare to ATAI and RARE?
According to the Biotechnology industry distribution chart, uniQure NV ranks #505 out of 956 companies for Debt-to-Equity. This places uniQure NV in the lower half of its industry. The industry median Debt-to-Equity is 0.16. uniQure NV's value of 0.19 is 18.8% above this benchmark. While the company's 10-year median is 0.30 vs. the industry median of 0.16, uniQure NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. uniQure NV's current Debt-to-Equity of 0.19 is 18.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on uniQure NV and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. uniQure NV's current Debt-to-Equity is 0.19, which is 37% below median its own 10-year median of 0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is uniQure NV stock overvalued right now?
Based on GuruFocus' analysis, uniQure NV (LTS:0EE0) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.88, compared to a current price of $49.90 — trading 533.2% above its estimated fair value. The current Debt-to-Equity is 0.19, which is 37% below median its 10-year median of 0.30 and 18.8% above the Biotechnology industry median of 0.16. uniQure NV's overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For uniQure NV (LTS:0EE0), the current Debt-to-Equity is 0.19 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is uniQure NV (LTS:0EE0) Overvalued in 2026?
Based on GuruFocus' analysis, uniQure NV stock appears to be overvalued.
The current stock price of $49.90 is trading 533.2% above its estimated GF Value™ of $7.88.
GuruFocus considers uniQure NV to be Significantly Overvalued.
Key valuation signals for LTS:0EE0:
Debt-to-Equity: 0.19 (37% below median its 10-year median of 0.30)
GF Value™: $7.88 vs. price of $49.90 (533.2% above fair value)
Industry Position: 18.8% above the Biotechnology median (#505 of 956)
No single metric tells the full story. See the LTS:0EE0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
37GF Score
Get the complete analysis for LTS:0EE0
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0EE0 has been successfully added to your 
